Drug Interactions between fosphenytoin and moxifloxacin / triamcinolone
This report displays the potential drug interactions for the following 2 drugs:
- fosphenytoin
- moxifloxacin/triamcinolone
Interactions between your drugs
triamcinolone moxifloxacin
Applies to: moxifloxacin / triamcinolone and moxifloxacin / triamcinolone
MONITOR CLOSELY: Concomitant administration of corticosteroids may potentiate the risk of tendinitis and tendon rupture associated with fluoroquinolone treatment. The mechanism is unknown. Tendinitis and tendon rupture have most frequently involved the Achilles tendon, although cases involving the rotator cuff (the shoulder), the hand, the biceps, and the thumb have also been reported. Some have required surgical repair or resulted in prolonged disability. Tendon rupture can occur during or up to several months after completion of fluoroquinolone therapy.
MANAGEMENT: Caution is recommended if fluoroquinolones are prescribed in combination with corticosteroids, particularly in patients with other concomitant risk factors (e.g., age over 60 years; recipient of kidney, heart, and/or lung transplant). Patients should be advised to stop taking the fluoroquinolone, avoid exercise and use of the affected area, and promptly contact their physician if they experience pain, swelling, or inflammation of a tendon. In general, fluoroquinolones should only be used to treat conditions that are proven or strongly suspected to be caused by bacteria and only if the benefits outweigh the risks.
References (7)
- (2002) "Product Information. Cipro (ciprofloxacin)." Bayer
- (2001) "Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical
- (2001) "Product Information. Avelox (moxifloxacin)." Bayer
- Khaliq Y, Zhanel GG (2003) "Fluoroquinolone-Associated Tendinopathy: A Critical Review of the Literature." Clin Infect Dis, 36, p. 1404-1410
- van der Linden PD, Sturkenboom MC, Herings RM, Leufkens HM, Rowlands S, Stricker BH (2003) "Increased risk of achilles tendon rupture with quinolone antibacterial use, especially in elderly patients taking oral corticosteroids." Arch Intern Med, 163, p. 1801-7
- FDA. U.S. Food and Drug Administration (2008) Information for Healthcare Professionals. Fluoroquinolone Antimicrobial Drugs. FDA Alert [7/8/2008]. http://www.fda.gov/cder/drug/InfoSheets/HCP/fluoroquinolonesHCP.htm
- (2017) "Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.
triamcinolone fosphenytoin
Applies to: moxifloxacin / triamcinolone and fosphenytoin
MONITOR: Phenytoin and other hydantoins may induce the CYP450 3A4 hepatic metabolism of corticosteroids and increase their clearance and decrease their half-lives, possibly reducing their therapeutic efficacy. In addition, results of the dexamethasone adrenal suppression test may be unreliable in patients concurrently taking phenytoin. Hydrocortisone appears to be affected to a lesser extent than other corticosteroids. Some corticosteroids have also been reported to cause increases or decreases in serum phenytoin levels; however, data have been inconsistent.
MANAGEMENT: Patients should be closely monitored for clinical and laboratory evidence of reduced corticosteroid effects and changes in phenytoin concentrations during concomitant therapy. Some patients may require increased corticosteroid dosages.
References (6)
- Frey BM, Frey FJ (1984) "Phenytoin modulates the pharmacokinetics of prednisolone and the pharmacodynamics of prednisolone as assessed by the inhibition of the mixed lymphocyte reaction in humans." Eur J Clin Invest, 14, p. 1-6
- Wong DD, Longenecker RG, Liepman M, Baker S, LaVergne M (1985) "Phenytoin-dexamethasone: a possible drug-drug interaction." JAMA, 254, p. 2062-3
- Lackner TE (1991) "Interaction of dexamethasone with phenytoin." Pharmacotherapy, 11, p. 344-7
- Lawson LA, Blouin RA, Smith RB, Rapp RP, Young AB (1981) "Phenytoin-dexamethasone interaction: a previously unreported observation." Surg Neurol, 16, p. 23-4
- Haque N, Thrasher K, Werk EE, Jr Knowles HC, Jr Sholiton LJ (1972) "Studies on dexamethasone metabolism in man: effect of diphenylhydantoin." J Clin Endocrinol Metab, 34, p. 44-50
- Stjernholm MR, Katz FH (1975) "Effects of diphenylhydantoin, phenobarbital, and diazepam on the metabolism of methylprednisolone and its sodium succinate." J Clin Endocrinol Metab, 41, p. 887-93
Drug and food interactions
No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.